Xvivo Perfusion Q4: First impression

Redeye's first impressions on the Q4 results. Sales came in slightly lower than we expected at SEK 60. 3m vs. our SEK 63.

3m. The gross margin was lower than expected at 69% vs. our expectation of 77%.

The deviations prove the low visibility at present and that the new business area Abdominal proved to have lower margins than we anticipated. We believe that sales will start to recover, while some uncertainty will persist during the first half of the current year. There was a gradual recovery that started in the third quarter but to which extent the pandemic will continue to affect intensive care units during 2021 remains to be seen.